You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Combined treatment with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke

https://doi.org/10.1136/ebm.7.2.42

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Lancet 358, 1033. PROGRESS Collaborative Group.. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.. Sep 29;. :. –41.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with a history of stroke or transient ischaemic attack (TIA), is perindopril alone or combined with indapamide more effective than placebo for reducing fatal or non-fatal stroke?

    Design

    Two* randomised (allocation concealed†), blinded {patients, clinicians, data collectors, outcome assessors, data analysts, and manuscript writers}‡,† placebo controlled trials with a mean follow up of 3.9 years (Perindopril Protection against Recurrent Stroke Study [PROGRESS]).

    Setting

    172 centres from 10 countries.

    Patients

    6105 patients (mean age 64 y, 70% men) who had a history of stroke or TIA in the previous 5 years, had no definite indication for or contraindication to an angiotensin-converting enzyme (ACE) inhibitor, and were clinically stable for ≥ 2 weeks after their most recent vascular event. 6102 patients (> 99%) completed follow up for fatal events.

    Intervention

    Some patients were …

    View Full Text

    Footnotes

    • ↵* The authors disagree with our reporting of their study as 2 separate trials.

    • ↵† See glossary.

    • ↵‡ Information provided by author.

    • Sources of funding: Servier Pharmaceuticals; Health Research Council of New Zealand; National Health and Medical Research Council of Australia.

    • For correspondence: not available.